X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AJANTA PHARMA VENUS REMEDIES/
AJANTA PHARMA
 
P/E (TTM) x -692.7 24.7 - View Chart
P/BV x 0.2 10.2 2.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VENUS REMEDIES   AJANTA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
AJANTA PHARMA
Mar-16
VENUS REMEDIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,720 12.7%   
Low Rs821,103 7.4%   
Sales per share (Unadj.) Rs365.6194.6 187.9%  
Earnings per share (Unadj.) Rs1.545.2 3.3%  
Cash flow per share (Unadj.) Rs37.950.3 75.4%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs382.5132.0 289.7%  
Shares outstanding (eoy) m11.4488.77 12.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.47.3 5.7%   
Avg P/E ratio x101.031.2 323.5%  
P/CF ratio (eoy) x4.028.1 14.1%  
Price / Book Value ratio x0.410.7 3.7%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m1,717125,299 1.4%   
No. of employees `0001.0NA-   
Total wages/salary Rs m3242,570 12.6%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,18317,275 24.2%  
Other income Rs m20166 12.1%   
Total revenues Rs m4,20317,442 24.1%   
Gross profit Rs m8125,807 14.0%  
Depreciation Rs m417451 92.5%   
Interest Rs m38049 776.7%   
Profit before tax Rs m355,474 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,460 1.2%   
Profit after tax Rs m174,014 0.4%  
Gross profit margin %19.433.6 57.7%  
Effective tax rate %51.626.7 193.4%   
Net profit margin %0.423.2 1.7%  
BALANCE SHEET DATA
Current assets Rs m2,7717,639 36.3%   
Current liabilities Rs m1,9312,715 71.1%   
Net working cap to sales %20.128.5 70.4%  
Current ratio x1.42.8 51.0%  
Inventory Days Days12543 289.3%  
Debtors Days Days5479 68.3%  
Net fixed assets Rs m5,3286,914 77.1%   
Share capital Rs m114177 64.7%   
"Free" reserves Rs m4,17711,442 36.5%   
Net worth Rs m4,37611,721 37.3%   
Long term debt Rs m1,911149 1,284.8%   
Total assets Rs m8,42814,814 56.9%  
Interest coverage x1.1112.9 1.0%   
Debt to equity ratio x0.40 3,441.0%  
Sales to assets ratio x0.51.2 42.6%   
Return on assets %4.727.4 17.2%  
Return on equity %0.434.2 1.1%  
Return on capital %6.646.5 14.2%  
Exports to sales %055.1 0.0%   
Imports to sales %20.56.0 341.7%   
Exports (fob) Rs mNA9,527 0.0%   
Imports (cif) Rs m8581,038 82.7%   
Fx inflow Rs m010,422 0.0%   
Fx outflow Rs m8581,678 51.1%   
Net fx Rs m-8588,744 -9.8%   
CASH FLOW
From Operations Rs m4693,264 14.4%  
From Investments Rs m29-2,093 -1.4%  
From Financial Activity Rs m-464-1,186 39.1%  
Net Cashflow Rs m35-15 -233.1%  

Share Holding

Indian Promoters % 32.9 73.8 44.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 1.6 11.6%  
FIIs % 0.6 7.6 7.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.0 390.6%  
Shareholders   20,121 20,968 96.0%  
Pledged promoter(s) holding % 36.4 4.4 828.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - DR. DATSONS LABS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS